一例Kallmann综合征患者双基因突变分析

doi:10.3969/j.issn.1006-7795.2014.06.017

摘要/Abstract

摘要：

目的分析Kallmann综合征(Kallmann syndrome,KS)患者KS1 (Kallmann syndrome 1,KAL1),前动力蛋白2(prokineticin 2,PROK2)和前动力蛋白受体2(prokineticin receptor 2,PROKR2)3个基因的突变情况。方法 ① 采用放射免疫分析法检测激素水平,超声扫描评估腹部结构,脑部磁共振成像(magnetic resonance imaging,MRI)检测嗅球、脑沟和内耳的结构。② 运用聚合酶链式反应(polymerase chain reaction,PCR),结合PCR产物直接测序技术分析KAL1、PROK2和PROKR2 3个基因外显子突变。③ 分别利用SIFT、Polyphen和Mutation Taster 3种生物信息学平台进行了错义位点和多态性位点的功能分析。结果 ① 患者青春期发育不良,嗅觉减退,其父母无症状。② 在患者基因组中找到2个KAL1杂合突变位点(Ile 565 Thr和Ser 570 Thr),5个KAL1基因单核苷酸多态性位点(single nucleotide polymorphism,SNP):Val 534 Ile、Val 560 Phe、Gly 567 Ser、Lys 666 Met和Agr 668 His,以及一个PROKR2纯合突变位点(Tyr 113 His)。同时也在患者父母基因组中检测到PROKR2杂合突变位点(Y113H)。③ 生物信息学分析结果显示I565T、S570T和Y113H(PROKR2)3个位点可能是该患者的致病基因位点。结论这2个新的突变位点还未在中国人群中报道过,这也是国内报道的第1例同时带有2个KAL1突变和一个PROKR2突变的KS患者,表明该患者可能是一个双基因遗传的KS患者。

关键词: Kallmann综合征, KAL1基因, PROKR2基因, 突变

Abstract:

Objective To analyze the mutation of Kallmann syndrome 1(KAL1), prokineticin(PROK2) and prokineticin receptor 2(PROKR2) in a family, which has a 13-year-old son with Kallmann syndrome(KS). Methods ① Hormone levels were measured by immunoradiometric assay, abdomen structures were assessed by abdominal ultrasound scan, brain magnetic resonance imaging(MRI) was used to visualize the olfactory bulbs, sulci, and inner ears; ② The exon sequences of the three genes(KAL1, PROK2 and PROKR2) were screened for a mutation by direct sequencing; ③ SIFT, Polyphen and MutationTaster were used as a complementary approach to assess the significance of polymorphisms and missense mutations. Results ① The patient had sexual infantilism, and the MRI of the head revealed the dysplasia of olfactory bulbs and olfactory tract; the parents of this patient had normal pubertal development, serum gonadotropin and estradiol concentrations, and their MRI results showed normal olfactory bulbs; ② In KAL1 gene, two novel mutations(I565T and S570T) and five previously described polymorphisms(V534I, V560F, G567S, K666M and R668H) were detected in this patient. In PROKR2 gene, a homozygous Y113H was presented in this patient, and this mutation was also detected in the heterozygous state in his parents; ③ I565T, Y113H (PROKR2) and S570T may be the harmful variation according to our stringent analysis. Conclusion To date, these two novel mutations have not yet been reported in the Chinese population, and this is the first case of KS patient who exhibited two-point mutation in KAL1 and was also carried a missense mutation in PROKR2, thus indicating a possible digenic inheritance of the disease in this individual.

Key words: Kallmann syndrome, KAL1, PROKR2, mutation

中图分类号:

R588

曹曦, 谢荣荣, 信中, 杨金奎. 一例Kallmann综合征患者双基因突变分析[J]. 首都医科大学学报, 2014, 35(6): 765-770.

Cao Xi, Xie Rongrong, Xin Zhong, Yang Jinkui. Analysis of mutations in patients with Kallmann syndrome[J]. Journal of Capital Medical University, 2014, 35(6): 765-770.

参考文献

[1] Hu Y, Tanriverdi F, MacColl G S, et al. Kallmann's syndrome: molecular pathogenesis[J]. Int J Biochem Cell Biol, 2003,35(8):1157-1162.
[2] Fechner A, Fong S, McGovern P. A review of Kallmann syndrome: genetics, pathophysiology, and clinical management[J]. Obstet Gynecol Surv, 2008,63 (3):189-194.
[3] Ribeiro R S, Vieira T C, Abucham J. Reversible Kallmann syndrome: report of the first case with a KAL1 mutation and literature review[J]. Eur J Endocrinol, 2007,156(3):285-290.
[4] Franco B, Guioli S, Pragliola A, et al. A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules[J]. Nature, 1991,353(6344):529-536.
[5] Dode C, Levilliers J, Dupont J M, et al. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome[J]. Nat Genet, 2003,33(4):463-465.
[6] Falardeau J, Chung W C, Beenken A, et al. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice[J]. J Clin Invest, 2008,118(8):2822-2831.
[7] Pitteloud N, Zhang C, Pignatelli D, et al. Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism[J]. Proc Natl Acad Sci U S A, 2007,104(44):17447-17452.
[8] Dode C, Teixeira L, Levilliers J, et al. Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2[J]. PLoS Genet, 2006,2(10):e175.
[9] Kim H G, Ahn J W, Kurth I, et al. WDR11, a WD protein that interacts with transcription factor EMX1, is mutated in idiopathic hypogonadotropic hypogonadism and Kallmann syndrome[J]. Am J Hum Genet, 2010,87(4):465-479.
[10] Tsai P S, Gill J C. Mechanisms of disease: Insights into X-linked and autosomal-dominant Kallmann syndrome[J]. Nat Clin Pract Endocrinol Metab, 2006,2(3):160-171.
[11] Ng P C, Henikoff S. SIFT: Predicting amino acid changes that affect protein function[J]. Nucleic Acids Res, 2003,31(13):3812-3814.
[12] Adzhubei I A, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations[J]. Nat Methods, 2010,7(4):248-249.
[13] Schwarz J M, Rodelsperger C, Schuelke M, et al. MutationTaster evaluates disease-causing potential of sequence alterations[J]. Nat Methods, 2010,7(8):575-576.
[14] Kim S H, Hu Y, Cadman S, et al. Diversity in fibroblast growth factor receptor 1 regulation: learning from the investigation of Kallmann syndrome[J]. J Neuroendocrinol, 2008,20(2):141-163.
[15] Tsuge T, Shimokawa T, Horikoshi S, et al. Polymorphism in promoter region of Fcalpha receptor gene in patients with IgA nephropathy[J]. Hum Genet, 2001,108(2):128-133.
[16] Yamada R, Tanaka T, Unoki M, et al. Association between a single-nucleotide polymorphism in the promoter of the human interleukin-3 gene and rheumatoid arthritis in Japanese patients, and maximum-likelihood estimation of combinatorial effect that two genetic loci have on susceptibility to the disease[J]. Am J Hum Genet, 2001,68(3):674-685.
[17] Cole L W, Sidis Y, Zhang C, et al. Mutations in prokineticin 2 and prokineticin receptor 2 genes in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum[J]. J Clin Endocrinol Metab, 2008,93(9):3551-3559.
[18] Badano J L, Katsanis N. Beyond Mendel: an evolving view of human genetic disease transmission[J]. Nat Rev Genet, 2002,3(10):779-789.
[19] Carlton V E, Harris B Z, Puffenberger E G, et al. Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT[J]. Nat Genet, 2003,34(1):91-96.
[20] Pitteloud N, Quinton R, Pearce S, et al. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism[J]. J Clin Invest, 2007,117(2):457-463.
[21] Gonzalez-Martinez D, Kim S H, Hu Y, et al. Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfate-dependent mechanism[J]. J Neurosci, 2004,24(46):10384-10392.
[22] Dode C, Hardelin J P. Kallmann syndrome: fibroblast growth factor signaling insufficiency?[J]. J Mol Med(Berl), 2004,82(11):725-734.
[23] Gao Y Q, Danciger M, Ozgul R K, et al. Association of the Asn306Ser variant of the SP4 transcription factor and an intronic variant in the beta-subunit of transducin with digenic disease[J]. Mol Vis, 2007,13:287-292.
[24] Muntoni F, Bonne G, Goldfarb L G, et al. Disease severity in dominant Emery Dreifuss is increased by mutations in both emerin and desmin proteins[J]. Brain, 2006,129(Pt 5):1260-1268.
[25] Tosch V, Rohde H M, Tronchere H, et al. A novel PtdIns3P and PtdIns(3,5) P2 phosphatase with an inactivating variant in centronuclear myopathy[J]. Hum Mol Genet, 2006,15(21):3098-3106.